Cas:80265-04-9 4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside manufacturer & supplier

Chemical Name:4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside

CAS.NO:80265-04-9

Synonyms:4-Methylumbelliferyl-2-Acetamido-2-Deoxy-alpha-D-Glucopyranoside;GlcNAc1-|A-4MU;4-Methylumbelliferyl 2-Acetamido-2-deoxy-|A-D-glucopyranoside

Molecular Formula:C₁₈H₂₁NO₈

Molecular Weight:379.36100

HS Code:

Physical and Chemical Properties:

Melting point:224-225ºC

Boiling point:732.169ºC at 760 mmHg

Density:1.48 g/cm3

Index of Refraction:

PSA:138.46000

Exact Mass:379.12700

LogP:

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-Methylumbelliferyl-2-Acetamido-2-Deoxy-alpha-D-Glucopyranoside chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Methylumbelliferyl 2-Acetamido-2-deoxy-|A-D-glucopyranoside physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Methylumbelliferyl 2-Acetamido-2-deoxy-|A-D-glucopyranoside Use and application,4-Methylumbelliferyl 2-Acetamido-2-deoxy-|A-D-glucopyranoside technical grade,usp/ep/jp grade.

Related News: As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters. 4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside manufacturer The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside supplier To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early. 4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside vendor To persuade doctors to stop treatment for a traditionally continuous therapy, AbbVie and J&J likely also need to show that doing so won’t hurt patients’ chance at successful retreatment if their cancer does rebound early. 4-methylumbelliferyl-2-acetamido-2-deoxy-alpha-d-glucopyranoside factory As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.